Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Investigational Product Administered to Adults with CIDP
Efficacy and Safety of Nipocalimab in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor: Janssen Research & Development
Enrolling: Male and Female Patients
IRB Number: AAAU0824
U.S. Govt. ID: NCT05327114
Contact: Jorge Cabrera: / jec2273@cumc.columbia.edu
Additional Study Information: This is a multicenter, Phase 2/3 study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Adults 18 yrs old or greater at the time of signing the informed consent.
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jorge Cabrera
jec2273@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE